Premium
MABp1 targeting interleukin‐1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open‐label extension period
Author(s) -
Kanni T.,
Argyropoulou M.,
Dinarello C. A.,
Simard J.,
GiamarellosBourboulis E. J.
Publication year - 2021
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.14333
Subject(s) - hidradenitis suppurativa , adalimumab , medicine , dermatology , open label , extension (predicate logic) , tumor necrosis factor alpha , computer science , disease , clinical trial , programming language